Oxford Biomedica PLC Total Voting Rights (5701Y)
02 Gennaio 2020 - 12:41PM
UK Regulatory
TIDMOXB
RNS Number : 5701Y
Oxford Biomedica PLC
02 January 2020
Oxford Biomedica
Total Voting Rights
Oxford, UK - 2 January 2020: Oxford Biomedica plc ("Oxford
Biomedica" or "the Company") (LSE: OXB), announces that in
accordance with the FCA's Disclosure Guidance and Transparency Rule
5.6.1, the Company's issued share capital as at the close of
business on 31 December 2019 consisted of 76,859,131 ordinary
shares of 50 pence each ("Ordinary Shares"). There are no Ordinary
Shares held in treasury.
Accordingly, the total number of voting rights in Oxford
Biomedica plc at the date of this notice is 76,859,131.
The above figure (76,859,131) may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Oxford Biomedica plc under the FCA's Disclosure
Guidance and Transparency Rules.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, Axovant Gene
Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the
UK Cystic Fibrosis Gene Therapy Consortium and Imperial
Innovations, through which it has long-term economic interests in
other potential gene and cell therapy products. Oxford Biomedica is
based across several locations in Oxfordshire, UK and employs more
than 480 people. Further information is available at
www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREAFFAEDPEEFA
(END) Dow Jones Newswires
January 02, 2020 06:41 ET (11:41 GMT)
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Apr 2023 a Apr 2024